Literature DB >> 8037610

Combination of plasma exchange and continuous hemofiltration as temporary metabolic support for patients with acute liver failure.

S Matsubara1.   

Abstract

The combination of plasma exchange and continuous hemofiltration was applied to patients with acute liver failure, and its clinically advantageous effects were evaluated. This procedure was found to be a powerful approach in decreasing patient morbidity; however, the effect was temporary and the patients finally died. Efforts to eliminate the hepatitis virus, which is the main etiology of hepatic necrosis in Japan, are urgent to salvage patients with fulminant liver failure.

Entities:  

Mesh:

Year:  1994        PMID: 8037610     DOI: 10.1111/j.1525-1594.1994.tb02217.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  5 in total

1.  Liver transplantation and artificial liver support in fulminant hepatic failure.

Authors:  X F Zhu; G H Chen; X S He; M Q Lu; G D Wang; C J Cai; Y Yang; J F Huang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Combined blood purification for treating acute fatty liver of pregnancy complicated by acute kidney injury: a case series.

Authors:  Wan Xin Tang; Zhong Ying Huang; Ze Jun Chen; Tian Lei Cui; Ling Zhang; Ping Fu
Journal:  J Artif Organs       Date:  2011-11-26       Impact factor: 1.731

3.  Extracorporeal continuous portal diversion plus temporal plasmapheresis for "small-for-size" syndrome.

Authors:  Peng Hou; Chao Chen; Yu-Liang Tu; Zi-Man Zhu; Jing-Wang Tan
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

4.  Hybrid artificial liver support system for treatment of severe liver failure.

Authors:  Jian-He Gan; Xia-Qiu Zhou; Ai-Lan Qin; Er-Ping Luo; Wei-Feng Zhao; Hong Yu; Jie Xu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

5.  Changes in peripheral CD4+CD25(high) regulatory T cells in the acute-on-chronic liver failure patients with plasma exchange treatment.

Authors:  Wei-lin Mao; Yu-Feng Lou; Bo Ye; Sha Lin; Yue-mei Chen; Yu Chen
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.